Anne Kristine Anstensrud1, Espen Molden2,3, Hans Jørgen Haug4, Rehman Qazi1, Hysen Muriq1, Linn E Fosshaug1,5, Olav Spigset6,7, Erik Øie8,9. 1. Department of Internal Medicine, Diakonhjemmet Hospital, PO BOX 23, Vinderen, N-0319, Oslo, Norway. 2. Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway. 3. Department of Pharmacy, University of Oslo, Oslo, Norway. 4. Faculty of Medicine, University of Oslo, Oslo, Norway. 5. Center for Heart Failure Research, University of Oslo, Oslo, Norway. 6. Department of Clinical Pharmacology, St. Olav's University Hospital, Trondheim, Norway. 7. Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. 8. Department of Internal Medicine, Diakonhjemmet Hospital, PO BOX 23, Vinderen, N-0319, Oslo, Norway. Erik.Oie@diakonsyk.no. 9. Center for Heart Failure Research, University of Oslo, Oslo, Norway. Erik.Oie@diakonsyk.no.
Abstract
PURPOSE: The β-1 adrenergic receptor blocker metoprolol is primarily metabolized by the polymorphic enzyme cytochrome P 450 2D6 (CYP2D6), an enzyme with substantial genetic heterogeneity. Our purpose was to investigate the impact of CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction (MI). METHODS: We included 136 patients with MI discharged on treatment with metoprolol with a recommendation to the general practitioner (GP) to increase the metoprolol dose up to 200 mg/day within 2 months if possible. At follow-up, metoprolol dosage after up-titration, metoprolol steady-state trough plasma concentrations, hemodynamic parameters, potential metoprolol-induced adverse drug reactions and number of visits to the GP were measured. CYP2D6 genotyping including the reduced-function variant alleles CYP2D6*9, CYP2D6*10 and CYP2D6*41 was performed after end of follow-up. RESULTS: According to the genotype-defined CYP2D6 phenotypes, 30% of the patients were metoprolol extensive metabolizers (EMs), 55% intermediate metabolizers (IMs) and 13% poor metabolizers (PMs; carriers of non-coding and reduced-function variant included). Dose-adjusted metoprolol trough concentrations were significantly higher in IM (2-fold) and PM (6.2-fold) groups vs. the EM group (p < 0.001). Only 35% of patients in the PM group achieved the primary end point, i.e. reaching at least 85% of the expected maximum heart rate (HR) during exercise, compared with 78% in the EM group (p < 0.01), and maximum observed HR at exercise was significantly lower in the PM group vs. the EM group (129 ± 5 vs. 142 ± 2 bpm, p < 0.007). In contrast, metoprolol maintenance dose, blood pressure, exercise capacity, number of visits at the GP and frequency and severity of self-reported potential metoprolol-related adverse drug reactions were not significantly different between the groups. CONCLUSION: Using a comprehensive CYP2D6 genotyping panel, the present study demonstrates a > 6-fold increase of dose-adjusted plasma metoprolol trough concentration in CYP2D6 PMs vs. EMs with a parallel lower increase in achieved maximum HR during exercise but without association between genotype and frequency or severity of self-reported adverse drug effects. This may indicate that CYP2D6 PMs potentially could benefit of the increased plasma concentration per dose in a naturalistic setting.
PURPOSE: The β-1 adrenergic receptor blocker metoprolol is primarily metabolized by the polymorphic enzyme cytochrome P 450 2D6 (CYP2D6), an enzyme with substantial genetic heterogeneity. Our purpose was to investigate the impact of CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction (MI). METHODS: We included 136 patients with MI discharged on treatment with metoprolol with a recommendation to the general practitioner (GP) to increase the metoprolol dose up to 200 mg/day within 2 months if possible. At follow-up, metoprolol dosage after up-titration, metoprolol steady-state trough plasma concentrations, hemodynamic parameters, potential metoprolol-induced adverse drug reactions and number of visits to the GP were measured. CYP2D6 genotyping including the reduced-function variant alleles CYP2D6*9, CYP2D6*10 and CYP2D6*41 was performed after end of follow-up. RESULTS: According to the genotype-defined CYP2D6 phenotypes, 30% of the patients were metoprolol extensive metabolizers (EMs), 55% intermediate metabolizers (IMs) and 13% poor metabolizers (PMs; carriers of non-coding and reduced-function variant included). Dose-adjusted metoprolol trough concentrations were significantly higher in IM (2-fold) and PM (6.2-fold) groups vs. the EM group (p < 0.001). Only 35% of patients in the PM group achieved the primary end point, i.e. reaching at least 85% of the expected maximum heart rate (HR) during exercise, compared with 78% in the EM group (p < 0.01), and maximum observed HR at exercise was significantly lower in the PM group vs. the EM group (129 ± 5 vs. 142 ± 2 bpm, p < 0.007). In contrast, metoprolol maintenance dose, blood pressure, exercise capacity, number of visits at the GP and frequency and severity of self-reported potential metoprolol-related adverse drug reactions were not significantly different between the groups. CONCLUSION: Using a comprehensive CYP2D6 genotyping panel, the present study demonstrates a > 6-fold increase of dose-adjusted plasma metoprolol trough concentration in CYP2D6 PMs vs. EMs with a parallel lower increase in achieved maximum HR during exercise but without association between genotype and frequency or severity of self-reported adverse drug effects. This may indicate that CYP2D6 PMs potentially could benefit of the increased plasma concentration per dose in a naturalistic setting.
Authors: Per Ole M Gundersen; Arne Helland; Olav Spigset; Solfrid Hegstad Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2018-04-28 Impact factor: 3.205
Authors: Issam Zineh; Amber L Beitelshees; Andrea Gaedigk; Joseph R Walker; Daniel F Pauly; Kathleen Eberst; J Steven Leeder; Michael S Phillips; Craig A Gelfand; Julie A Johnson Journal: Clin Pharmacol Ther Date: 2004-12 Impact factor: 6.875
Authors: Dennis T Ko; Patricia R Hebert; Christopher S Coffey; Artyom Sedrakyan; Jeptha P Curtis; Harlan M Krumholz Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: I S Hamadeh; T Y Langaee; R Dwivedi; S Garcia; B M Burkley; T C Skaar; A B Chapman; J G Gums; S T Turner; Y Gong; R M Cooper-DeHoff; J A Johnson Journal: Clin Pharmacol Ther Date: 2014-03-17 Impact factor: 6.875